🧴 Rosacea Trigger Identification Treatment Simulator

Logging a Rosacea Trigger-Diary Entry

Short placeholder: one flushing episode is recorded right after exposure.

• 5: Entry fields (Placeholder: exposure, time, severity)
• <1 hr: Recall window (Placeholder logging guidance)
• Flush/Papule: Entry types (Placeholder categories tracked)
• Pattern data: Goal (Placeholder purpose note)

What gets logged

Placeholder: exposure type, timing, and flare severity noted.

Why single entries are not enough

Placeholder: one entry cannot confirm a real trigger pattern.

Placeholder tip: log every flare, not just bad ones.

Identifying the Dominant Trigger Across Entries

Short placeholder: repeated entries expose which exposure recurs most.

• 5: Candidate triggers (Placeholder tracked categories)
• 8+: Entries for confidence (Placeholder recommended minimum)
• % match: Pattern metric (Placeholder scoring method)
• Heat/Alcohol: Common dominant (Placeholder survey finding)

Counting recurring exposures

Placeholder: tally each trigger type across all logged entries.

Confidence rises with volume

Placeholder: more entries sharpen the dominant-trigger signal.

Placeholder tip: two weeks of logging is usually enough.

Classifying Rosacea Subtype Alongside Triggers

Short placeholder: clinician confirms subtype independent of triggers.

• 3: Subtypes tracked (Placeholder classification set)
• Flushing: ETR hallmark (Placeholder visible sign)
• Papules: Papulopustular sign (Placeholder visible sign)
• Thickening: Phymatous sign (Placeholder visible sign)

Why subtype matters

Placeholder: treatment differs sharply by rosacea subtype.

Overlap is common

Placeholder: patients can show more than one subtype at once.

Placeholder tip: reassess subtype at each visit.

Matching Trigger Pattern and Subtype to Therapy

Short placeholder: the matched treatment addresses the confirmed pathway.

• Brimonidine: Flushing therapy (Placeholder topical option)
• Ivermectin: Inflammatory therapy (Placeholder topical option)
• Laser: Phymatous therapy (Placeholder procedural option)
• Avoidance plan: Always included (Placeholder baseline step)

Matching logic

Placeholder: subtype picks the drug class, trigger picks avoidance steps.

When confidence is low

Placeholder: more diary entries requested before committing therapy.

Placeholder tip: match confidence above 70% before starting.

Combined Avoidance Plus Matched Therapy Outcome

Short placeholder: pairing both approaches outperforms either alone.

• ~25%: Avoidance alone (Placeholder estimated reduction)
• ~35%: Therapy alone (Placeholder estimated reduction)
• ~60–80%: Combined plan (Placeholder estimated reduction)
• Monthly: Review cadence (Placeholder follow-up interval)

Why combining works

Placeholder: avoidance lowers flare triggers while therapy treats pathway.

Ongoing adjustment

Placeholder: plan is revised as new diary entries arrive.

Placeholder tip: re-run matching after any subtype change.

Treatment branches by subtype